CICC：梵语制药产品的维护超过行业评级，并将目

CICC发布了一份研究报告，该报告将增加6249亿欧元/566.4亿欧元的净利润186.5％/138.3％，以确认BD收入。股票的当前价格对应于2025/2026的收益率11.3倍/12.3倍。由于该动作反映了对创新药物的核心产品的一定程度的反思，并保持了绩效行业的上部评级，因此该银行的上升速度增长了39.9％，达到39.9％，相当于2025年的价格回报率的13.0倍，而2026年价格频段的比率为2026年，最高36.50美元。该公司宣布的收益率为1H25，收入为43.56亿元人民币，年份降低0.8％。股东归因的净收入为13.58亿元人民币，年龄增长了24.6％，年龄为24.6％，调整后的净收入为11.36亿元人民币，在线CO -IN CO -IN CO -IN CO -IN LINEN MANGERAME TREPUTION的预期增加了2.1％。 CICC的主要视图是： 1H25中央公司商业产品的销售ARE在压力下相对 根据该消息，Tebio 1H25的收入为23.71亿元人民币，上一年下降了4.2％，占收入的54.4％。 Yibio的收入为3.46亿元人民币，比上一年减少了12.1％，而Cybor的收入为1.1亿元人民币，比上一年下降了10.4％，占两者总收入的10.5％。该公司在脱毛部门1H25地区的收入为6.9亿元人民币，届时增长了23.8％，收入占15.8％。其中，曼迪的收入为6.82亿元。 CDMO业务在1H25的收入为1.01亿元，比上一年增加了76.1％。梵文的收入为6.42亿元人民币，一年增长7.6％。 它在四个主要区域深处生长，并拥有丰富的开发管道品种 根据公告，在1H25阶段结束时，该公司的研发管INcludes 30种发育，血液学和肿瘤，自身免疫，眼科和肾脏病。 SSGJ-705（双抗P-1/HER2抗体）在中国实体肿瘤患者II+高级患者中发现，美国批准了FDA。 SSS59（3 MUC17/CD3/CD28抗体）目前正在对实体瘤的I期临床试验中。 外国合作继续被实施，并继续实施创新成果。 1）外部批准：1H25公司授予辉瑞SSGJ-707（PD-1/VEGF）双anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-抗anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-Athi-Athi-Athi-Athi-Athi-Athi-Athi-Anti-Anti-Anti-Anti-Anti-Athi-Athi-Athi-Athi-Athi-Athi-Athi-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-ai-Aan Ti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Ai-A nti-anti-抗anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti- SSGJ-707的价值被认可。该银行认为，预计该公司将考虑未来的治疗，以及辉瑞ADC管道和下一代ADC IO+的位置。 2）产品简介：调整国家医疗保险目录的初步审查列表，该清单已通过与Haihe毒品的口头合作进入2025年。 III期与Hanyu Pharmaceutical合作注射Allegglutid体重减轻的临床迹象完成了患者的注册。与Yingen Biologics获得公司DB-1303（HER2） ADC）中国大陆，香港和澳门的商业合作权。 风险警告：降低集中式收购价格超出了预期，竞争的增加，研究和开发失败以及新产品的商业化少于预期。 官方NINA Finance帐户 24-最新信息和财务视频的流离失所，以及扫描QR码以关注更多粉丝（Sinafinance）